News FDA orders blindness risk warning to GLP-1 agonist labels FDA has ordered all GLP-1 receptor agonist manufacturers to add a warning to their product labels for a rare eye condition that can cause blindness.
News Oura smart ring to be used in weight-loss outcomes trial Oura has launched a trial to see if data collected from its smart rings can help scientists understand physiological changes with obesity treatment.
News Lilly's triple G overpowers Ozempic in diabetes trial Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.
News CagriSema helps women lose 25% of their weight in study Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy in women.
News GLP-1 drugs linked to reduced acute schizophrenia episodes The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.
News Lilly's Zepbound enhances Taltz efficacy in psoriasis study A study has shown that the efficacy of Lilly's psoriasis therapy Taltz is improved when it is given in combination with weight-loss drug Zepbound.
News Third Rock in $2bn drug-hunting pact with China's Funnel New Chinese biotech Funnel has signed a $2bn-plus partnership with Third Rock Ventures, focused on using its AI platform to discover novel biologics.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.